Table 5 Cumulative risks of cancer in PMS2 carriers

All carriers:

Any cancer

4.5%

(0.010)

18.9%

(0.022)

36.7%

(0.030)

57.9%

(0.036)

CRC, all carriers

3.1%

(0.009)

10.8%

(0.017)

21.7%

(0.026)

34.2%

(0.036)

CRC, women

2.9%

(0.012)

7.6%

(0.020)

16.5%

(0.031)

25.4%

(0.045)

CRC, men

3.3%

(0.013)

14.6%

(0.029)

27.8%

(0.041)

43.9%

(0.054)

Endometrial cancer

1.4%

(0.008)

7.3%

(0.021)

18.3%

(0.036)

26.1%

(0.046)

c.989-1G > T carriers:

Any cancer

5.3%

(0.017)

17.9%

(0.032)

37.5%

(0.047)

62.8%

(0.056)

CRC, all carriers

3.6%

(0.015)

10.5%

(0.026)

21.6%

(0.041)

37.5%

(0.058)

CRC, women

4.5%

(0.022)

7.3%

(0.029)

16.8%

0.049)

30.0%

(0.074)

CRC, men

3.9%

(0.022)

14.5%

(0.045)

27.8%

(0.068)

46.5%

(0.088)

Endometrial cancer

2.2%

(0.015)

6.4%

(0.028)

21.6%

(0.058)

26.5%

(0.072)

c.989-1G > T carriers excluded:

Any cancer

4%

(0.013)

19.4%

(0.029)

36.1%

(0.038)

54.5%

0.047)

CRC, all carriers

2.7%

(0.011)

11.0%

(0.023)

21.9%

(0.033)

31.8%

(0.044)

CRC, women

1.7%

(0.012)

7.9%

(0.027)

16.4%

(0.041)

21.9%

(0.054)

CRC, men

3.9%

(0.019)

14.7%

(0.038)

27.9%

(0.052)

42.0%

(0.068)

Endometrial cancer

1.7%

(0.012)

8.0%

(0.030)

16.0%

(0.044)

26.3%

(0.062)